UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
      ---------------------------------------------------------------------

                                   FORM 10-QSB

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  For the quarterly period ended March 31, 2006

                          Commission File No. 333-94265

                              Liska Biometry, Inc.
      ---------------------------------------------------------------------
        (Exact Name of small business issuer as specified in its charter)

                 FLORIDA                                06-1562447
     --------------------------------     ---------------------------------
     (State or other jurisdiction of      (IRS Employer Identification No.)
      incorporation or organization)

                            100 Main Street Suite 230
                           Dover, New Hampshire, 03820
     -----------------------------------------------------------------------
                    (Address of Principal Executive Offices)

                                 1 877 77 LISKA
          (Telephone number, including area code, of agent for service)

                                   Copies to:
                                   ----------

                            Virginia K. Sourlis, Esq.
                                  The Galleria
                                 2 Bridge Avenue
                               Red Bank, NJ 07701
                                 (732) 530-9007
                               Fax (732) 530-9008
                               www.SourlisLaw.com
--------------------------------------------------------------------------------

Registrant has filed all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12 months and has been
subject to such filing requirements for the past 90 days. |X| Yes |_| No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

--------------------------------------------------------------------------------

 As of May 15, 2006, we had 37,973,036 shares of our common stock outstanding.


                              LISKA BIOMETRY, INC.
                            INDEX TO QUARTERLY REPORT
                                 ON FORM 10-QSB

<PAGE>
                                                                            Page
PART I -   FINANCIAL INFORMATION
           Item 1 - Financial Statements
                     Balance Sheet (Unaudited)                                 3
                     Statements of Operations (Unaudited)                      4
                     Statements of Cash Flows (Unaudited)                      5
                     Notes to Financial Statements                             6
           Item 2 - Management's Discussion and Analysis or Plan of
                       Operations                                              9
           Item 3 - Controls and Procedures                                   13
PART II -  OTHER INFORMATION
           Item 6 - Exhibits and Reports on Form 8-K                          14
           Signatures                                                         15

--------------------------------------------------------------------------------

                                       2
<PAGE>


                              Liska Biometry, Inc.
                          (A Development Stage Company)
                           Consolidated Balance Sheet
                              as of March 31, 2006
                                   (Unaudited)

Assets

Current assets:
    Cash                                               $      1,667
    Prepaid expenses                                         15,511
    Debt discount                                            77,877
    Deposit on acquisition                                  100,000
                                                       ------------
         Total Current Assets                               195,055
                                                       ------------

Fixed assets, net                                            45,811
Note receivable                                             125,000
                                                       ------------

                                                       $    365,866
                                                       ============

Liabilities and stockholders' (deficit)

Current liabilities:
   Bank overdraft                                      $      3,044
   Accounts payable & accrued expenses                      445,094
   Notes payable                                            350,000
   Due to investors                                         110,000
                                                       ------------
          Total current liabilities                         908,138
                                                       ------------

Stockholders' (deficit):
   Preferred stock, no par value,
      10,000,000 shares authorized, none outstanding
   Common stock, no par value,
      100,000,000 shares authorized,
        36,023,036 shares issued and outstanding         11,474,222
   Receivable for common stock                           (1,375,000)
   Additional paid in capital                             1,016,834
  (Deficit) accumulated during the development stage    (11,615,010)
                                                       ------------
                                                           (498,954)
                                                       ------------
  Other comprehensive income:
    Currency translation adjustment                         (43,318)
                                                       ------------
          Total stockholders' (deficit)                    (542,272)
                                                       ------------

                                                       $    365,866
                                                       ============


      See the accompanying notes to the consolidated financial statements.

                                       3
<PAGE>

                              Liska Biometry, Inc.
                         (A Development Stage Company)
                     Consolidated Statements of Operations
                Three Months Ended March 31, 2006 and 2005, and
                  Inception (August 1, 2000) to March 31, 2006
                                  (Unaudited)

<TABLE>
<CAPTION>
                                                           Three months    Three months
                                                              Ended           Ended        Inception to
                                                            March 31,        March 31,       March 31,
                                                               2006            2005            2006
                                                           ------------    ------------    ------------
<S>                                                        <C>             <C>             <C>
Sales                                                      $       --      $       --      $      8,000
Cost of goods sold                                                 --              --               892
                                                           ------------    ------------    ------------
Gross profit                                                       --              --             7,108
                                                           ------------    ------------    ------------
Operating expenses:
   Impairment of license                                           --              --            58,812
   Selling, general and administrative expenses -
     Non cash stock compensation                                 78,750         292,145       8,207,290
     Other                                                      432,892         299,981       3,195,143
                                                           ------------    ------------    ------------
                                                                511,642         592,126      11,461,245
                                                           ------------    ------------    ------------
(Loss) from operations                                         (511,642)       (592,126)    (11,454,137)
                                                           ------------    ------------    ------------
Other income (expense):
   Other income                                                    --              --               250
   Interest (expense)                                          (161,123)           --          (161,123)
                                                           ------------    ------------    ------------
                                                               (161,123)           --          (160,873)
                                                           ------------    ------------    ------------
Net (loss)                                                     (672,765)       (592,126)    (11,615,010)
Comprehensive income:
   Currency translation adjustment                              (13,958)         (3,603)        (43,318)
                                                           ------------    ------------    ------------
Comprehensive (loss)                                       $   (686,723)   $   (595,729)   $(11,658,328)
                                                           ============    ============    ============
Per share information - basic and fully diluted:
  Weighted average shares outstanding                        35,628,592      23,942,599
                                                           ============    ============
  Net (loss) per share                                     $      (0.02)   $      (0.02)
                                                           ============    ============
</TABLE>

      See the accompanying notes to the consolidated financial statements.

                                       4
<PAGE>

                              Liska Biometry, Inc.
                          (A Development Stage Company)
                      Consolidated Statements of Cash Flows
                 Three Months Ended March 31, 2006 and 2005, and
                  Inception (August 1, 2000) to March 31, 2006
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                           Three           Three
                                                           Months         Months
                                                           Ended           Ended         Inception to
                                                          March 31,       March 31,        March 31,
                                                            2006            2005             2006
                                                        -----------      -----------      -----------
<S>                                                     <C>              <C>          <C> <C>
Cash flows from operating activities:
Net cash (used in) operating activities                 $  (289,090)     $  (218,102)     $(2,425,045)

Cash flows from investing activities:
  Note receivable                                          (125,000)            --           (125,000)
  Payment for license                                          --               --            (50,000)
  Deposit on acquisition                                       --               --           (100,000)
  Purchase of fixed assets                                     --            (16,579)        (107,298)
                                                        -----------      -----------      -----------
Net cash (used in) investing activities                    (125,000)         (16,579)        (382,298)
                                                        -----------      -----------      -----------
Cash flows from financing activities:
  Capital contributions                                        --               --              8,878
  Common shares issued and subscriptions for cash              --             48,000        2,542,452
  Cancelled subscription                                       --               --             (9,000)
  Common shares repurchased for cash                           --               --           (200,000)
  Proceeds from notes payable                               425,000             --            475,000
  Repayment of notes payable                                (75,000)            --            (75,000)
  Proceeds (repayment) investor loans                        46,000            2,448          110,000
                                                        -----------      -----------      -----------
Net cash provided by financing activities                   396,000           50,448        2,852,330
                                                        -----------      -----------      -----------
Net increase (decrease) in cash                             (18,090)        (184,233)          44,987
Effect of currency translation on cash                      (13,958)            --            (43,320)
Beginning - cash balance                                     33,715          245,641             --
                                                        -----------      -----------      -----------
Ending - cash balance                                   $     1,667      $    61,408      $     1,667
                                                        ===========      ===========      ===========
Supplemental cash flow information:
  Cash paid for income taxes                            $      --        $      --        $      --
                                                        ===========      ===========      ===========
  Cash paid for interest                                $      --        $      --        $      --
                                                        ===========      ===========      ===========
</TABLE>

                                       5

      See the accompanying notes to the consolidated financial statements.

<PAGE>

                              LISKA BIOMETRY, INC.
                          (A DEVELOPMENT STAGE COMPANY)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 March 31, 2006
                                   (UNAUDITED)

(1) Basis Of Presentation

The accompanying unaudited consolidated financial statements have been prepared
in accordance with generally accepted accounting principles (GAAP) for interim
financial information and Item 310(b) of Regulation S-B. They do not include all
of the information and footnotes required by GAAP for complete financial
statements. In the opinion of management, all adjustments (consisting only of
normal recurring adjustments) considered necessary for a fair presentation have
been included.

The results of operations for the periods presented are not necessarily
indicative of the results to be expected for the full year. For further
information, refer to the financial statements of the Company as of December 31,
2005, and for the two years then ended, and the period from inception (August 1,
2000) to December 31, 2005, including notes thereto included in the Company's
Form 10-KSB.

(2) Basis of Reporting

The Company's financial statements are presented on a going concern basis, which
contemplates the realization of assets and satisfaction of liabilities in the
normal course of business.

The Company has experienced a significant loss from operations as a result of
its investment necessary to achieve its operating plan, which is long-range in
nature. For the three months ended March 31, 2006, and the period from inception
to March 31, 2006, the Company incurred net losses of $672,765 and $11,615,010
respectively and has working capital and stockholder deficits of $713,083 and
$542,272 respectively at March 31, 2006. In addition, the Company has no revenue
generating operations.

The Company's ability to continue as a going concern is contingent upon its
ability to attain profitable operations and secure financing. In addition, the
Company's ability to continue as a going concern must be considered in light of
the problems, expenses and complications frequently encountered by entrance into
established markets and the competitive environment in which the Company
operates.

The Company is pursuing equity financing for its operations. Failure to secure
such financing or to raise additional capital or borrow additional funds may
result in the Company depleting its available funds and not being able pay its
obligations.

The financial statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the possible inability of
the Company to continue as a going concern.


                                       6
<PAGE>

(3) Note Receivable

The note receivable represents a loan to Sogedex of Paris, France denominated as
100,000 Euros. The note receivable bears interest at 4.5%. The note is
convertible into common stock of Sogedex. In connection with the loan, the
Company also received an option to purchase 80% of the outstanding stock of
Sogedex for approximately 2,400,000 Euros. The initial term of the option
expires on July 31 2006, but may be extended through December 31, 2006, by
providing additional funds to Sogedex in the amount of 170,000 Euros. If the
note is not converted into Sogedex common stock or the option to purchase
additional stock is not exercised, the note is due in 20 quarterly installments
commencing in 2007 and ending in 2012.

(4) Notes Payable

The Company received gross proceeds of $425,000 during the quarter ended March
31, 2006. A loan of $125,000 was provided by Digital Card Systems. It bears
interest at 12% and is due on or before May 31, 2006. Repayment of $75,000 was
made during the quarter ended March 31, 2006, and the remaining balance of
$50,000 was paid subsequent to the end of the quarter.

A loan of $300,000 was received from CAMOFI Master LDC, an affiliate of
Centrecourt Asset Management LLC ("CAMOFI"). The note bears interest at 8% and
is due on April 30, 2006. As additional consideration for the loan, the Company
issued 500,000 shares of common stock and 300,000 warrants (see Note 5). The
Company valued the stock at its fair market value of $150,000 which was recorded
as additional paid in capital and debt discount. The Company valued the warrants
at $83,631 using the Black Scholes option pricing model and recorded the amount
as additional paid in capital and debt discount. The aggregate debt discount of
$233,631 will be amortized to interest expense over the three-month term of the
loan. During the quarter ended March 31 2006, $155,754 was charged to interest
expense.

The CAMOFI loan was secured by the assets of the Company and by a pledge of
3,300,000 shares of the Company's common stock owned by the Company's president.

(5) Stockholders' (Deficit)

During the three months ended March 31, 2006, the Company issued 1,881,773
shares of common stock. The total includes 1,069,273 previously subscribed
shares that were issued pursuant to a Form S-8 filed on December 30, 2005. The
Company also issued 312,500 shares for services rendered pursuant to employment
and consulting contracts. The shares were valued at their fair market value of
$78,750, all of which was charged to operations during the quarter. The Company
issued 500,000 shares as additional consideration pursuant to the note payable
agreement with CAMOFI. The aggregate fair value of these shares was $150,000
(based upon quoted market value on the loan agreement date).

During the quarter ended March 31, 2006, the Company issued 300,000 warrants as
additional consideration pursuant to the note payable agreement with CAMOFI.
Each warrant entitles the holder to purchase one share of common stock at an
exercise price of $0.33 and all warrants expire on July 31, 2009.

During the three months ended March 31, 2006, the Company did not issue any
stock options.


                                       7
<PAGE>

The following table summarizes information about fixed-price stock options at
March 31, 2006:

<TABLE>
<CAPTION>
                                       Outstanding
                        Weighted         Weighted         Weighted-
                         Average         Average           Average            Exercisable
      Exercise            Number       Contractual        Exercise         Number      Exercise
       Prices          Outstanding        Life             Price         Exercisable    Price
     -------------     -----------     -----------      -----------      -----------   --------
     <S>                   <C>          <C>                 <C>             <C>         <C>
     $.32                  295,000      10 years            $.32               --       $ .32
     $.39                  650,000      10 years            $.39               --       $ .39
     $.61                   30,000      10 years            $.61               --       $ .61
     $.64 to $.65          350,000       9 years            $.64            350,000     $1.00
</TABLE>


(6) Earnings Per Share

The Company calculates net income (loss) per share as required by Statement of
Financial Accounting Standards (SFAS) 128, "Earnings per Share." Basic earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares outstanding for the period. Diluted earnings
(loss) per share is calculated by dividing net income (loss) by the weighted
average number of common shares and dilutive common stock equivalents
outstanding. During periods when they would be anti-dilutive common stock
equivalents, if any, are not considered in the computation. During the period
ending March 31, 2006, common stock equivalents of 1,625,000 were excluded
because they would have been anti-dilutive.

(7) Commitments and Contingencies

During the periods covered by these financial statements the Company issued
shares of common stock without registration under the Securities Act of 1933.
Although the Company believes that the sales did not involve a public offering
of its securities and that the Company did comply with the "safe harbor"
exemptions from registration, it could be liable for rescission of the sales if
such exemptions were found not to apply and this could have a material negative
impact on the Company's financial position and results of operations. In
addition, the Company issued shares of common stock pursuant to Form S-8
registration statements. The Company believes that it complied with the
requirements of Form S-8 in regard to these issuances, however if it were
determined that there were violations of the provisions of Form S-8 the Company
could be subject to enforcement proceedings.

During the periods covered by these financial statements the Company entered
into several employment, consulting and other agreements with third parties.
Although the Company obtained settlement releases from a majority of the
parties, settlement releases were not entered into with some of these parties or
the settlement releases were verbal agreements. Future contingencies, which
cannot be estimated by management, may exist for the above matters including but
not limited to issuance of capital stock and other financial obligations and may
have a material negative impact on the Company's financial position and results
of operations.

(9) Pending Merger with Digital Card Systems

In December 2005 the company signed a letter of Intent to merge operations with
Digital Card Systems of Acton, Ma. As per the agreement, the company is to issue
25,000,000 shares of common stock for all of the stock in DCS. In addition the
company paid DCS $100,000 in accordance with a standstill agreement through June
30, 2006.

In February 2006 the company signed a definitive agreement to merge operations
with Digital Card Systems of Acton, MA. The agreement is subject to certain
terms and conditions including but not limited to audits and due diligence.
There can be no assurance that the Company will be able to complete this merger.

                                       8
<PAGE>

(10) Subsequent Events

Subsequent to March 31, 2006, the Company exercised its option to extend the
maturity date of the CAMOFI loan to July 31, 2006.

Subsequent to March 31, 2006, the Company issued 450,000 shares of common stock
for services pursuant to employment or consultant contracts. On May 11, 2006,
the Company sold 1,500,000 shares of common stock to an individual pursuant to a
subscription agreement for net cash proceeds of $150,000.


Item 2 Management's Discussion and Analysis or Plan of Operation

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report contains "forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934 and is subject to the safe harbor created by those sections. We intend
to identify forward-looking statements in this report by using words such as
"believes," "intends," "expects," "may," "will," "should," "plan," "projected,"
"contemplates," "anticipates," "estimates," "predicts," "potential," "continue,"
or similar terminology. These statements are based on the Company's beliefs as
well as assumptions the Company made using information currently available to
us. The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise. Because these statements reflect the Company's current
views concerning future events, these statements involve risks, uncertainties,
and assumptions. Actual future results may differ significantly from the results
discussed in the forward-looking statements. These risks include changes in
demand for the Company's products, changes in the level of operating expenses,
changes in general economic conditions that impact consumer behavior and
spending, product supply, the availability, amount, and cost of capital for the
Company and the Company's use of such capital, and other risks discussed in this
report. Additional risks that may affect our performance are discussed under
"Risk Factors Associated with Our Business" in our Form 10-KSB for the fiscal
year ended December 31, 2005. Readers are cautioned not to place undue reliance
on the forward-looking statements contained in this report. We disclaim any
obligation to update forward-looking statements. All references to "we", "our",
"us", of refer to Liska Biometry, Inc., and it predecessors, operating
divisions, and subsidiaries.

CRITICAL ACCOUNTING POLICIES

There were no changes to the Company's critical accounting policies in the first
quarter of 2006. Critical accounting policies are those applications of
accounting principles or practices that require considerable judgment,
estimation, or sensitivity analysis by management.

--------------------------------------------------------------------------------

PLAN OF OPERATIONS

We plan to complete our current Plan of Operations over a period of six to 12
months. At the present time we do not have sufficient cash resources to complete
our Plan of Operations. We have not had sufficient cash resources to conduct our
Plan of Operations since we adopted our new business plan of developing
fingerprint encoding and authentication technology. Therefore, full
implementation of our Plan of Operations is contingent upon receiving adequate
financing to meet the remaining costs of our estimate of $1,823,500.


                                       9
<PAGE>

Our Plan of Operations for the Next 12 Months:

RESEARCH AND DEVELOPMENT

In January 2003 we developed a preliminary demonstration model of our proposed
fingerprint technology, which provided only a conceptual guide for future
development. We continued our development throughout 2003 and attempted to
improve our core technology and implement changes in our core software; however,
most of our development occurred from September 2004 to March 2006, in which we
made further changes to our core software. As reflected below in our Plan of
Operations, we will continue to develop our core technology as financing becomes
available.


SOFTWARE ALGORITHM DEVELOPMENT

Using third party live-scan fingerprint scanners, we can now demonstrate the
proof of concept of our proprietary software concepts, illustrating the
differentiating features of embedded software algorithms - that is, the
capability to measure the stable content of a fingerprint image and to express
it as a numeric output and match that number with the numeric output from both
live and stored finger scans to authenticate individuals. A workable prototype
has been developed and is now in final productization, which is contingent upon
us receiving financing, which we may be unable to obtain.

GENERAL & ADMINISTRATIVE EXPENSES

We intend to expend funds for general and administrative expenses such as:
insurance expense, payroll tax, rent expense, legal expenses, professional fees,
telephony and internet access, travel & entertainment, payroll expenses,
professional fees and offices expenses. We have centralized management of the
corporation in Dover, NH, and over the period of this plan will consolidate
resources and space in Ottawa, Ontario Canada, where we will lower our costs of
rent and manpower, focusing totally on Research and Development of our BIN-2
technology, with limited marketing support for Canada and the Middle East. Our
chief business activity will occur in Dover NH.

The remaining estimated annual costs associated with these expenditures is
approximately $625,000


DEVELOP AND INITIATE MARKETING EFFORT

Our marketing personnel have conducted a preliminary market analysis and have
developed a market segmentation strategy that allows for product diversification
and expansion which uses our existing technical developments as leverage and
allows us to demonstrate our unique product within market verticals and
horizontal segments that span them.

o     Horizontal Segmentation: the Company intends to promote wide-spread
      acceptance of the BIN(TM) concept for large scale ID management projects
      via a software product offering and IP licensing model. The focus is on
      large government contracts, both in North America and abroad.

o     Vertical Segmentation: the Company intends to build its industry
      credibility by providing customized niche applications for specific
      BIN(TM) related applications in direct response to customer requests.
      These applications will be industry specific and will entail a large
      service component. The focus is on high probability pilot contracts for
      large-scale identity management, transportation and fleet security.


                                       10
<PAGE>

We will continue to develop strategic partner alliances to collaborate on our
marketing and technological integration efforts. Such strategic partners may
include the following:

o     Fingerprint biometrics hardware system vendors;
o     Systems Integrators, defense contractors
o     Original Equipment Manufacturers (OEMs), Channel Partners
o     Other distribution channels that target military and commercial security
      markets.

We intend to intensify our foreign sales and marketing efforts in Europe, Canada
and the Middle East where we have received a significant reception for our
customized solutions offerings.

In addition, we will acquire other market information and contacts by joining
key industry groups and hiring industry analysts, attending trade shows,
traveling to meet potential clients/partners and designing print media/web based
promotional strategies.

The annual cost associated with this marketing effort is approximately $555,000.

PRODUCT APPLICATIONS RESEARCH AND DEVELOPMENT INITIATIVE FOCUS

We will continue to develop our proprietary software algorithms, with focused
R&D program milestones and deliverables planned for 2006. Our goal in this
regard is to deliver a demonstrable, error-free application for identity
authentication as well as the baseline BIN-2 product software development kit
(SDK), which will allow us to integrate our product in a variety of systems
already fielded. The remaining annual cost associated with expanding the product
application and R&D functions is approximately $250,000.


SUMMARY OF ESTIMATED COSTS

---------------------------------------------- --- -----------------------
CEO                                            $                   90,000
---------------------------------------------- --- -----------------------
Capital Expenditures                                               84,500
---------------------------------------------- --- -----------------------
Sr. VP Operations                                                  80,000
---------------------------------------------- --- -----------------------
VP Global Solutions                                                80,000
---------------------------------------------- --- -----------------------
Chief Software Architect                                           64,500
---------------------------------------------- --- -----------------------
Chief Engineer                                                     64,500
---------------------------------------------- --- -----------------------
R&D Engineer                                                       60,000
---------------------------------------------- --- -----------------------
Administration Manager                                             40,000
---------------------------------------------- --- -----------------------
Director of Business Development                                   80,000
---------------------------------------------- --- -----------------------
Marketing Effort                                                  555,000
---------------------------------------------- --- -----------------------
General & Administrative                                          625,000
---------------------------------------------- --- -----------------------
TOTAL                                          $                1,823,500
---------------------------------------------- --- -----------------------


                                       11
<PAGE>

--------------------------------------------------------------------------------

REVENUES

We cannot determine whether our revenues, if any, will ever be sufficient to
produce a positive cash flow or result in net profits. You should carefully
consider the discussion appearing below under "Liquidity and Capital Resources".
We earned no revenues during Fiscal Year 2005 or to date in Fiscal Year 2006 or
in connection with our business plan of developing fingerprint encoding and
authentication technology. We do not expect to earn significant operating
revenues in the foreseeable future. Our losses are expected to continue,
principally as a result of our estimated expenditures of $1,823,500, as
reflected above.

--------------------------------------------------------------------------------

LIQUIDITY AND CAPITAL RESOURCES

As of March 31, 2006, we had limited cash resources of only $1,667. We do not
have any other internal sources of working capital. We did not receive any
revenues during our Fiscal Year 2005 or to date in Fiscal Year 2006. We do not
anticipate earning revenues until such time that we obtain financing to
implement our Plan of Operations, if ever. Even if we complete our Plan of
Operations, there are no assurances that we will successfully develop a
marketable product.

During Fiscal Year 2005 and date in Fiscal Year 2006, our operating expenses
have exceeded our revenues, which has been $0. We have insufficient working
capital to fund our planned growth and ongoing operating expenses. As a result,
we expect to continue to experience significant negative operating cash flow for
the foreseeable future. Our existing working capital will not be sufficient to
fund the continued implementation of our Plan of Operations during the next 12
months and to meet our general operating expenses. If we do not have sufficient
working capital to implement our Plan of Operations, we may have to cease
operations.

We have no alternative Plan of Operations. In the event that we do not receive
financing, if our financing is inadequate or if we do not adequately implement
an alternative Plan of Operations that enables us to conduct operations without
having received adequate financing, we may have to liquidate our business and
undertake any or all of the following actions:


o     Sell or dispose of our assets, if any;
o     Pay our liabilities in order of priority, if we have available cash to pay
      such liabilities;
o     If any cash remains after we satisfy amounts due to our creditors,
      distribute any remaining cash to our shareholders in an amount equal to
      the net market value of our net assets;
o     File a Certificate of Dissolution with the State of Florida dissolve our
      corporation and close our business; and
o     Make the appropriate filings with the Securities and Exchange Commission
      so that we will no longer be required to file periodic and other required
      reports with the Securities and Exchange Commission, if, in fact, we are a
      reporting company at that time

Based upon our current assets, however, we will not have the ability to
distribute any cash to our shareholders.

If we have any liabilities that we are unable to satisfy and we qualify for
protection under the U.S. Bankruptcy Code, we may voluntarily file for
reorganization under Chapter 11 or liquidation under Chapter 7. Our creditors
may also file a Chapter 7 or Chapter 11 bankruptcy action against us. If our
creditors or we file for Chapter 7 or Chapter 11 bankruptcy, our creditors will
take priority over our shareholders. If we fail to file for bankruptcy under
Chapter 7 or Chapter 11 and we have creditors, such creditors may institute
proceedings against us seeking forfeiture of our assets, if any.


                                       12
<PAGE>

We do not know and cannot determine which, if any, of these actions we will be
forced to take.

If any of these foregoing events occur, you could lose your entire investment in
our shares.

There is substantial doubt about our ability to continue as a going concern as
we have suffered recurring losses from operations and have no established source
of revenue. Accordingly, our independent auditors included an explanatory
paragraph in their report on our December 31, 2005 financial statements
regarding concerns about our ability to continue as a going concern. Our
financial statements contain additional note disclosures describing the
circumstances that lead to this disclosure by our independent auditors.

--------------------------------------------------------------------------------

Item 3     Controls and Procedures

We maintain and are currently undertaking actions to improve disclosure controls
and procedures designed to ensure that information required to be disclosed in
reports filed under the Securities Exchange Act of 1934, as amended, is
recorded, processed, summarized and reported within the specified time periods.
As of the end of the period covered by this report, the Corporation's Chief
Executive Officer ("CEO") evaluated the effectiveness of the Corporation's
disclosure controls and procedures. Based on the evaluation, our CEO has
discovered a potential material weakness in our disclosure controls as they
relate to the documents supporting the issuance of equity securities. Our CEO
believes that the weaknesses did not affect the reporting or disclosure in our
annual or quarterly reports due to controls put in place during the current
quarter and compensating controls, such as the detailed review of these areas
subsequent to the time at which the agreements were entered into and during the
preparation of our quarterly and annual reports.

      These weaknesses are currently being addressed and actions are currently
being taken to improve our disclosure controls and procedures; and our CEO has
concluded that our disclosure controls and procedures, combined with
compensating controls are effective as of the end of the period covered by this
report in that information required to be disclosed in this 10QSB has been
recorded, processed, summarized and reported properly within the current fiscal
year. Although there was a change in our disclosure controls and procedures
during the quarter, there were no changes in our internal control over financial
reporting that occurred during our most recent six month period that have
materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

      The following is a summary of the weakness and deficiency that has been
identified and addressed:

      o     Deficiency related to the documentation, review and approval of
            certain sales under a Regulation S sale of securities by our
            authorized broker/dealer agents. At our most recent year-end, we
            identified a deficiency in controls related to documentation, review
            and approval of sales made under a series of Regulation S
            transactions. Such deficiencies resulted in our inability to obtain
            supporting documentation confirming the investor's intention to
            subscribe to the shares sold despite having received the funds from
            the broker/agent and despite having the certificates issued by our
            transfer agent. This deficiency did not exist for the private
            placements affected during the year.

      As a result of the findings above, we have implemented and will continue
to implement the following actions:


      o     We have appointed a part-time financial controller to support the
            preparation of financial statements and reports to be filed with the
            SEC.

      o     We are establishing procedures to improve our review and processing
            of non-accounting documentation and contracts, and specifically will
            require adequate documentation be provided concurrently with any
            future share subscriptions, regardless of type.


                                       13
<PAGE>

      o     We intend to periodically review our internal procedures and
            controls to ensure additional enhancements to our internal controls
            are installed as necessary to meet our operational needs. Outside
            consultants will be engaged to advise our management as areas of
            concern are identified.

      o     We intend to establish a Code of Ethics.

      o     We intend to hire a CFO

      Our management is committed to a sound internal control environment. We
believe we have committed adequate resources to the aforementioned reviews and
remedies. We believe that we have addressed the issue identified above, and we
believe that we are in the process of further improving our infrastructure,
personnel, processes and controls to help ensure that we are able to produce
accurate disclosures and financial statements with appropriate supporting
documentation on a timely basis.

--------------------------------------------------------------------------------

                            PART II OTHER INFORMATION

Item 2     Changes in Securities

During the quarter ending March 31, 2006, the Company issued 312, 500 shares for
services rendered.

The Company did not sell any unregistered securities for the three months ended
March 31, 2006:

The Company issued 500,000 shares to CAMOFI Masters LDC. In accordance with the
terms of the $300,000 loan. The Company issued 300,000 warrants with an exercise
price of $0.33 to CAMOFI Masters LDC. In accordance with the terms of the
$300,000 loan.

<TABLE>
<CAPTION>
<S>                  <C>                           <C>                          <C>
Date of Issuance     Description of Securities     Number of Shares Issued      Purchase Price
                     Issued
</TABLE>



Item 6     Exhibits and Reports on Form 8K
(a)        Exhibits


EXHIBIT
NUMBER    DESCRIPTION OF EXHIBIT
-------   ----------------------

3.1      Articles of Incorporation (1)

3.2      By-Laws (2)

31.1     Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and
         Rule 15d-14(a), promulgated under C the Securities Exchange Act of
         1934, as amended.

32.1     Certification of Chief Executive Officer pursuant to 18 U.S.C. Section
         1350, as adopted pursuant to C Section 906 of the Sarbanes-Oxley Act of
         2002.

--------------------------------------------------------------------------------


                                       14
<PAGE>

(1)   Denotes previously filed exhibits: filed on January 7, 2000 with 3045
      Corporation's Form SB-2 registration statement, file # 333-94265.

(2)   Denotes previously filed exhibits: filed on May 30, 2003 with Liska
      Biometry, Inc.'s Form 10-KSB for the period ended December 31, 2001.

We hereby incorporate the following additional documents by reference: our (a)
our Form 10-KSB for the year ended December 31st, 2005, which was filed on April
21st, 2006; for the year ended December 31, 2004 which was filed on April 21,
2005, December 31, 2003, which was filed on April 7, 2004, for the year, ended
December 31, 2002, which was filed on July 28, 2003; and for the year, ended
December 31, 2001 which was filed on May 30, 2003; (b) our Registration
Statement on Form SB-2 and all amendments thereto which was filed on January 7,
2000 and amended on February 8, 2000, March 1, 2000, March 14, 2000, April 3,
2000, and April 4, 2000; (c) our Forms 10-QSB for the periods ended March 31,
2005 which was filed on May 15, 2005; September 30, 2004 which was filed on
November 15, 2004; June 30, 2004 which was filed on August 16, 2004; March 31,
2004 which was filed on May 19, 2004; September 30, 2003 which was filed on
November 14, 2003; June 30, 2003 which was filed on August 15, 2003; March 31,
2003 which was filed on August 15, 2003; September 30, 2002 which was filed on
July 28, 2003; June 30, 2002 which was filed on May 30, 2003; March 31, 2002
which was filed on May 30, 2002; June 30, 2001 which was filed on April 4, 2002;
September 30, 2001 which was filed on April 4, 2002; March 31, 2001 which was
filed on May 21, 2001; August 31, 2000 which was filed on September 15, 2000;
May 31, 2000 which was filed on June 20, 2000; and February 29, 2000 which was
filed on April 14, 2000.

--------------------------------------------------------------------------------
SIGNATURES

      Pursuant to the requirements of Section 12 of the Securities and Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

                                                LISKA BIOMETRY, INC.

                                                Dated: May 22nd, 2006

                                                By: /s/ Christopher J. LeClerc
                                                ------------------------------
                                                Christopher J. LeClerc
                                                President and CEO
                                                (Principal Executive Officer)

                                                By: /s/ Christopher J. LeClerc
                                                ------------------------------
                                                Christopher J. LeClerc
                                                President and CEO
                                                (Principal Executive Officer)


                                    15